A Phase 2 interventional study of MM120 and Placebo in Anxiety Generalized, sponsored by Definium Therapeutics US, Inc.. Completed at 22 sites in United States. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Definium Therapeutics US, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 265 studies in Generalized Anxiety Disorder with a site in United States — 38 open to participants now, 53 under way, 9 of them phase 3. Generalized Anxiety Disorder · United States.
Among the 265 studies in Generalized Anxiety Disorder with a site in United States, this one is the 78th largest by enrollment of the 234 interventional ones that give a count, is one of 11 that started in 2022, is one of 21 in phase 2, and was the 206th registered.
518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.
Browse Generalized Anxiety Disorder studies →38 of the 265 studies in Generalized Anxiety Disorder with a site in United States are open now. Recruiting first, the newest first:
Virginia Polytechnic Institute and State University · Sites in United States
Ages 18–65
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18+
Intra-Cellular Therapies, Inc. · Sites in United States
Ages 18+
BTL Industries Ltd. · Sites in United States
Ages 22+
Intra-Cellular Therapies, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 86 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 52 (60%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
265 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 32 · Phase 3 51 · Phase 4 28
First in 1991; this study’s year is marked. 11 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 198 is above the median of 83 across 440 interventional studies indexed under Generalized Anxiety Disorder.
Median enrollment 90 across the 234 interventional studies, 220 across the 28 observational. Of the 199 that completed or were terminated, 90 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
83 of 265 have an industry lead sponsor. The 10 most frequent:
Definium Therapeutics US, Inc. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Definium Therapeutics US, Inc. has 3 studies filed under Generalized Anxiety Disorder — fewer than ten, so there is no comparison to draw.
20 of the studies in Generalized Anxiety Disorder with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07123467Phase 3Wayne State UniversityCannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder | 2027-08-31 |
| NCT06846320AbbVieStudy to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | 2026-11 |
| NCT06723158Boston UniversityOral Surgery Virtual Reality Glasses Study | 2026-12 |
| NCT04557891University of California, Los AngelesLow-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD) | 2026-12 |
| NCT05467683Jasper A. SmitsCO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy | 2026-12-01 |
Add all 20 to your calendar (.ics) → With an account.
Among the 265 studies in Generalized Anxiety Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, multi-center, randomized, double-blind, parallel-group, dose-finding study to assess the effect of 4 doses of MM120 (25, 50, 100 or 200 μg freebase-equivalent) for the treatment of anxiety symptoms in subjects diagnosed with generalized anxiety disorder (GAD).
The study will enroll approximately 200 male and female subjects 18 years to \< 75 years of age who meet DSM-5 criteria for GAD and have a minimum HAM-A Total Score of 20. Subjects on contraindicated concomitant medications, supplements or other therapeutics at Screening (Visit 1) will undergo a medication taper prior to advancing to Baseline (Visit 2).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A substance that is designed to have no therapeutic value.
Other: Placebo
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
Drug: MM120
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
Drug: MM120
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
Drug: MM120
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
Drug: MM120
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A).
Also known as: MM-120, DT120, lysergide tartrate
A substance that is designed to have no therapeutic value.
Dose Response
To investigate the dose-response relationship for different doses of MM120 versus placebo in change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score at Week 4. The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety: Anxious mood, Tension, Fears, Insomnia, Intellectual, Depressed mood, Somatic (muscular), Somatic (sensory), Cardiovascular symptoms, Respiratory symptoms, Gastrointestinal symptoms, Genitourinary symptoms, Autonomic symptoms, and Behavior at interview (general). The central rater assessed the extent to which the subject displayed each given criterion and gave a rating on a scale of 0-4, where 4 represents the most severe symptoms. Minimum score = 0, maximum score = 56. Scores are summed and the greater the total score, the more severe illness.
Time frame: 4 weeks
Dose Response
To investigate the dose-response relationship for different doses of MM120 versus placebo in change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score at Week 8. The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety: Anxious mood, Tension, Fears, Insomnia, Intellectual, Depressed mood, Somatic (muscular), Somatic (sensory), Cardiovascular symptoms, Respiratory symptoms, Gastrointestinal symptoms, Genitourinary symptoms, Autonomic symptoms, and Behavior at interview (general). The central rater assessed the extent to which the subject displayed each given criterion and gave a rating on a scale of 0-4, where 4 represents the most severe symptoms. Minimum score = 0, maximum score = 56. Scores are summed and the greater the total score, the more severe illness.
Time frame: 8 weeks
Change From Baseline in HAM-A Total Score
To determine the change from Baseline of 4 doses of MM120 (25, 50, 100 or 200 μg free base equivalent) compared to Placebo as measured by the change in HAM-A Total Score from Baseline to Week 4 Hamilton Anxiety Rating Scale (HAM-A) consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety: Anxious mood, Tension, Fears, Insomnia, Intellectual, Depressed mood, Somatic (muscular), Somatic (sensory), Cardiovascular symptoms, Respiratory symptoms, Gastrointestinal symptoms, Genitourinary symptoms, Autonomic symptoms, and Behavior at interview (general). The central rater assessed the extent to which the subject displayed each given criterion and gave a rating on a scale of 0-4, where 4 represents the most severe symptoms. Minimum score = 0, maximum score = 56. Scores are summed and the greater the total score, the more severe illness. Data shown are change in HAM-A Total Score from Baseline to Week 4
Time frame: 4 weeks
Change From Baseline in HAM-A Total Scores
To determine the change from Baseline in HAM-A total scores of 4 doses of MM120 (25, 50, 100 or 200 μg free base equivalent) compared with placebo from Baseline to Week 8. Hamilton Anxiety Rating Scale (HAM-A) consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety: Anxious mood, Tension, Fears, Insomnia, Intellectual, Depressed mood, Somatic (muscular), Somatic (sensory), Cardiovascular symptoms, Respiratory symptoms, Gastrointestinal symptoms, Genitourinary symptoms, Autonomic symptoms, and Behavior at interview (general). The central rater assessed the extent to which the subject displayed each given criterion and gave a rating on a scale of 0-4, where 4 represents the most severe symptoms. Minimum score = 0, maximum score = 56. Scores are summed and the greater the total score, the more severe illness. Data shown are change in HAM-A Total Score from Baseline to Week 8
Time frame: 8 weeks
Change From Baseline in HAM-A Total Scores
To determine the change from Baseline in HAM-A total scores of 4 doses of MM120 (25, 50, 100 or 200 μg free base equivalent) compared with placebo from Baseline to End of Study (Week 12). Hamilton Anxiety Rating Scale (HAM-A) consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety: Anxious mood, Tension, Fears, Insomnia, Intellectual, Depressed mood, Somatic (muscular), Somatic (sensory), Cardiovascular symptoms, Respiratory symptoms, Gastrointestinal symptoms, Genitourinary symptoms, Autonomic symptoms, and Behavior at interview (general). The central rater assessed the extent to which the subject displayed each given criterion and gave a rating on a scale of 0-4, where 4 represents the most severe symptoms. Minimum score = 0, maximum score = 56. Scores are summed and the greater the total score, the more severe illness. Data shown are change in HAM-A Total Score from Baseline to end of study (12 weeks)
Time frame: 12 weeks
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in depressive symptoms as measured by the MADRS. The Montgomery-Åsberg Depression Rating Scale (MADRS) - used to assess depression severity and to detect changes due to treatment. Questionnaire included 10 clinician-completed items. Each of 10 questions scored with a range of 0-6 points. An item score of 0 indicated item not present or normal, while an item score of 6 indicated severe or continuous presence of the symptoms. The total possible score was 60, and higher scores represented a more severe condition. A decrease in score by ≥ 50% indicated a response to treatment, and an actual score of ≤ 10 indicated a remission of symptoms.
Time frame: Week 1
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in depressive symptoms measured via the MADRS. The Montgomery-Åsberg Depression Rating Scale (MADRS) - used to assess depression severity and to detect changes due to treatment. Questionnaire included 10 clinician-completed items. Each of 10 questions scored with a range of 0-6 points. An item score of 0 indicated item not present or normal, while an item score of 6 indicated severe or continuous presence of the symptoms. The total possible score was 60, and higher scores represented a more severe condition. A decrease in score by ≥ 50% indicated a response to treatment, and an actual score of ≤ 10 indicated a remission of symptoms.
Time frame: Week 2
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in depressive symptoms measured via the MADRS. The Montgomery-Åsberg Depression Rating Scale (MADRS) - used to assess depression severity and to detect changes due to treatment. Questionnaire included 10 clinician-completed items. Each of 10 questions scored with a range of 0-6 points. An item score of 0 indicated item not present or normal, while an item score of 6 indicated severe or continuous presence of the symptoms. The total possible score was 60, and higher scores represented a more severe condition. A decrease in score by ≥ 50% indicated a response to treatment, and an actual score of ≤ 10 indicated a remission of symptoms.
Time frame: Week 4
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in depressive symptoms measured via the MADRS. The Montgomery-Åsberg Depression Rating Scale (MADRS) - used to assess depression severity and to detect changes due to treatment. Questionnaire included 10 clinician-completed items. Each of 10 questions scored with a range of 0-6 points. An item score of 0 indicated item not present or normal, while an item score of 6 indicated severe or continuous presence of the symptoms. The total possible score was 60, and higher scores represented a more severe condition. A decrease in score by ≥ 50% indicated a response to treatment, and an actual score of ≤ 10 indicated a remission of symptoms.
Time frame: Week 8
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in depressive symptoms measured via the MADRS. The Montgomery-Åsberg Depression Rating Scale (MADRS) - used to assess depression severity and to detect changes due to treatment. Questionnaire included 10 clinician-completed items. Each of 10 questions scored with a range of 0-6 points. An item score of 0 indicated item not present or normal, while an item score of 6 indicated severe or continuous presence of the symptoms. The total possible score was 60, and higher scores represented a more severe condition. A decrease in score by ≥ 50% indicated a response to treatment, and an actual score of ≤ 10 indicated a remission of symptoms.
Time frame: End of Study (Week 12)
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-S. The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. (minimum score 1, maximum score 7)
Time frame: Week 1
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-S. The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. (minimum score 1, maximum score 7)
Time frame: Week 2
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-S. The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. (minimum score 1, maximum score 7)
Time frame: Week 4
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-S. The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. (minimum score 1, maximum score 7)
Time frame: Week 8
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-S. The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. (minimum score 1, maximum score 7)
Time frame: End of Study (12 weeks)
Mean Clinical Global Impression - Improvement (CGI-I) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-I. The Clinical Global Impression - Improvement (CGI-I) was used to measure the clinician's assessment of how much the subject's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening. (minimum score 1, maximum score 7)
Time frame: Week 1
Mean Clinical Global Impression - Improvement (CGI-I) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-I. The Clinical Global Impression - Improvement (CGI-I) was used to measure the clinician's assessment of how much the subject's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening. (minimum score 1, maximum score 7)
Time frame: Week 2
Mean Clinical Global Impression - Improvement (CGI-I) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-I. The Clinical Global Impression - Improvement (CGI-I) was used to measure the clinician's assessment of how much the subject's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening. (minimum score 1, maximum score 7)
Time frame: Week 4
Mean Clinical Global Impression - Improvement (CGI-I) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-I. The Clinical Global Impression - Improvement (CGI-I) was used to measure the clinician's assessment of how much the subject's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening. (minimum score 1, maximum score 7).
Time frame: Week 8
Mean Clinical Global Impression - Improvement (CGI-I) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-I. The Clinical Global Impression - Improvement (CGI-I) was used to measure the clinician's assessment of how much the subject's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening. (minimum score 1, maximum score 7)
Time frame: End of Study (Week 12)
Change From Baseline in Patient Global Impression - Severity (PGI-S) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-S. The Patient Global Impression - Severity (PGI-S) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure disease severity (PGI-S). The PGI-S comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates more severe illness. (minimum score 1, maximum score 5)
Time frame: Week 1
Change From Baseline in Patient Global Impression - Severity (PGI-S) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-S. The Patient Global Impression - Severity (PGI-S) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure disease severity (PGI-S). The PGI-S comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates more severe illness. (minimum score 1, maximum score 5)
Time frame: Week 2
Change From Baseline in Patient Global Impression - Severity (PGI-S) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-S. The Patient Global Impression - Severity (PGI-S) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure disease severity (PGI-S). The PGI-S comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates more severe illness. (minimum score 1, maximum score 5)
Time frame: Week 4
Change From Baseline in Patient Global Impression - Severity (PGI-S) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-S. The Patient Global Impression - Severity (PGI-S) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure disease severity (PGI-S). The PGI-S comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates more severe illness. (minimum score 1, maximum score 5)
Time frame: Week 8
Change From Baseline in Patient Global Impression - Severity (PGI-S) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-S. The Patient Global Impression - Severity (PGI-S) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure disease severity (PGI-S). The PGI-S comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates more severe illness. (minimum score 1, maximum score 5)
Time frame: End of study (Week 12)
Mean Patient Global Impression - Change (PGI-C) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-C. The Patient Global Impression - Change (PGI-C) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure changes in disease severity (PGI-C). The PGI-C comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates change for the worse (worsening symptoms). (minimum score 1, maximum score 5)
Time frame: Week 1
Mean Patient Global Impression - Change (PGI-C) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-C. The Patient Global Impression - Change (PGI-C) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure changes in disease severity (PGI-C). The PGI-C comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates change for the worse (worsening symptoms). (minimum score 1, maximum score 5)
Time frame: Week 2
Mean Patient Global Impression - Change (PGI-C) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-C. The Patient Global Impression - Change (PGI-C) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure changes in disease severity (PGI-C). The PGI-C comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates change for the worse (worsening symptoms). (minimum score 1, maximum score 5)
Time frame: Week 4
Mean Patient Global Impression - Change (PGI-C) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-C. The Patient Global Impression - Change (PGI-C) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure changes in disease severity (PGI-C). The PGI-C comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates change for the worse (worsening symptoms). (minimum score 1, maximum score 5)
Time frame: Week 8
Change From Baseline in Patient Global Impression - Change (PGI-C) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-C. The Patient Global Impression - Change (PGI-C) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure changes in disease severity (PGI-C). The PGI-C comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates change for the worse (worsening symptoms). (minimum score 1, maximum score 5)
Time frame: End of Study (Week 12)
Change From Baseline in Sheehan Disability Scale (SDS) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in functional disability symptoms measured via the SDS. The Sheehan Disability Scale (SDS) is a composite of 3 self-rated items designed to measure the extent to which 3 major domains in the patient's life (work, social life/leisure activities and family life/home responsibilities) are functionally impaired by psychiatric or medical symptoms. Total score 0-30 (0 unimpaired, 30 highly impaired). Work/school (0-10); Social life (0-10); Family life/home responsibilities (0-10).
Time frame: Week 1
Change From Baseline in Sheehan Disability Scale (SDS) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in functional disability symptoms measured via the SDS. The Sheehan Disability Scale (SDS) is a composite of 3 self-rated items designed to measure the extent to which 3 major domains in the patient's life (work, social life/leisure activities and family life/home responsibilities) are functionally impaired by psychiatric or medical symptoms. Total score 0-30 (0 unimpaired, 30 highly impaired). Work/school (0-10); Social life (0-10); Family life/home responsibilities (0-10).
Time frame: Week 2
Change From Baseline in Sheehan Disability Scale (SDS) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in functional disability symptoms measured via the SDS. The Sheehan Disability Scale (SDS) is a composite of 3 self-rated items designed to measure the extent to which 3 major domains in the patient's life (work, social life/leisure activities and family life/home responsibilities) are functionally impaired by psychiatric or medical symptoms. Total score 0-30 (0 unimpaired, 30 highly impaired). Work/school (0-10); Social life (0-10); Family life/home responsibilities (0-10).
Time frame: Week 4
Change From Baseline in Sheehan Disability Scale (SDS) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in functional disability symptoms measured via the SDS. The Sheehan Disability Scale (SDS) is a composite of 3 self-rated items designed to measure the extent to which 3 major domains in the patient's life (work, social life/leisure activities and family life/home responsibilities) are functionally impaired by psychiatric or medical symptoms. Total score 0-30 (0 unimpaired, 30 highly impaired). Work/school (0-10); Social life (0-10); Family life/home responsibilities (0-10).
Time frame: Week 8
Change From Baseline in Sheehan Disability Scale (SDS) Total Scores
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in functional disability symptoms measured via the SDS. The Sheehan Disability Scale (SDS) is a composite of 3 self-rated items designed to measure the extent to which 3 major domains in the patient's life (work, social life/leisure activities and family life/home responsibilities) are functionally impaired by psychiatric or medical symptoms. Total score 0-30 (0 unimpaired, 30 highly impaired). Work/school (0-10); Social life (0-10); Family life/home responsibilities (0-10).
Time frame: End of Study (Week 12)
Improved Quality of Life as Measured by EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS)
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in quality of life. The EuroQol 5 Dimension 5 Level (EQ-5D-5L) was used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The VAS for the subject's health status scored as ranging from 0 = worst health you can imagine, to 100 = best health you can imagine.
Time frame: Week 1
Improved Quality of Life as Measured by EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS)
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in quality of life. The EuroQol 5 Dimension 5 Level (EQ-5D-5L) was used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The VAS for the subject's health status scored as ranging from 0 = worst health you can imagine, to 100 = best health you can imagine.
Time frame: Week 2
Improved Quality of Life as Measured by EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS)
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in quality of life. The EuroQol 5 Dimension 5 Level (EQ-5D-5L) was used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The VAS for the subject's health status scored as ranging from 0 = worst health you can imagine, to 100 = best health you can imagine.
Time frame: Week 4
Improved Quality of Life as Measured by EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS)
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in quality of life. The EuroQol 5 Dimension 5 Level (EQ-5D-5L) was used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The VAS for the subject's health status scored as ranging from 0 = worst health you can imagine, to 100 = best health you can imagine.
Time frame: Week 8
Improved Quality of Life as Measured by EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale (VAS)
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in quality of life. The EuroQol 5 Dimension 5 Level (EQ-5D-5L) was used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The VAS for the subject's health status scored as ranging from 0 = worst health you can imagine, to 100 = best health you can imagine.
Time frame: End of Study (12 weeks)
Improved Sleep as Measured by Pittsburgh Sleep Quality Index (PSQI)
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in sleep measured via the PSQI. The Pittsburgh Sleep Quality Index (PSQI) was used to assess sleep quality and disturbances over the preceding month. The questionnaire had a Component Score for each of these with a range of 0-3 points: Subjective sleep quality, Sleep latency, Sleep duration, Habitual sleep efficiency, Sleep disturbance, Use of sleeping medication, and Daytime dysfunction. The sum of the Component Scores = a Global Score. Global Score of 0 indicated no difficulty and a Global Score of 21 indicated severe difficulty in all areas.
Time frame: Week 4
Improved Sleep as Measured by Pittsburgh Sleep Quality Index (PSQI)
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in sleep measured via the PSQI. The Pittsburgh Sleep Quality Index (PSQI) was used to assess sleep quality and disturbances over the preceding month. The questionnaire had a Component Score for each of these with a range of 0-3 points: Subjective sleep quality, Sleep latency, Sleep duration, Habitual sleep efficiency, Sleep disturbance, Use of sleeping medication, and Daytime dysfunction. The sum of the Component Scores = a Global Score. Global Score of 0 indicated no difficulty and a Global Score of 21 indicated severe difficulty in all areas.
Time frame: Week 8
Improved Sleep as Measured by Pittsburgh Sleep Quality Index (PSQI)
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in sleep measured via the PSQI. The Pittsburgh Sleep Quality Index (PSQI) was used to assess sleep quality and disturbances over the preceding month. The questionnaire had a Component Score for each of these with a range of 0-3 points: Subjective sleep quality, Sleep latency, Sleep duration, Habitual sleep efficiency, Sleep disturbance, Use of sleeping medication, and Daytime dysfunction. The sum of the Component Scores = a Global Score. Global Score of 0 indicated no difficulty and a Global Score of 21 indicated severe difficulty in all areas.
Time frame: End of Study (Week 12)
Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Females
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in female subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
Time frame: Week 1
Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Females
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in female subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
Time frame: Week 2
Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Females
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in female subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
Time frame: Week 4
Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Females
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in female subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
Time frame: Week 8
Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Females
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in female subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
Time frame: End of Study (Week 12)
Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Males
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in male subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
Time frame: Week 1
Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Males
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in male subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
Time frame: Week 2
Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Males
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in male subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
Time frame: Week 4
Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Males
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in male subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
Time frame: Week 8
Improved Sexual Functioning as Measured by Arizona Sexual Experiences Questionnaire (ASEX) - Males
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in male subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
Time frame: End of Study (Week 12)
Summary of Sexual Dysfunction Rates (ASEX), Females, to Week 1
Number of Participants with sexual dysfunction n (%) vs Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
Time frame: Week 1
Summary of Sexual Dysfunction Rates (ASEX), Females, to Week 2
Number of Participants with sexual dysfunction n (%) vs Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
Time frame: Week 2
Summary of Sexual Dysfunction Rates (ASEX), Females, to Week 4
Number of Participants with sexual dysfunction n (%) vs Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
Time frame: Week 4
Summary of Sexual Dysfunction Rates (ASEX), Females, to Week 8
Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
Time frame: Week 8
Summary of Sexual Dysfunction Rates (ASEX), Females, to Week 12
Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
Time frame: End of Study (Week 12)
Summary of Sexual Dysfunction Rates (ASEX), Males, to Week 1
Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
Time frame: Week 1
Summary of Sexual Dysfunction Rates (ASEX), Males, to Week 2
Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
Time frame: Week 2
Summary of Sexual Dysfunction Rates (ASEX), Males, to Week 4
Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
Time frame: Week 4
Summary of Sexual Dysfunction Rates (ASEX), Males, to Week 8
Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
Time frame: Week 8
Summary of Sexual Dysfunction Rates (ASEX), Males, to Week 12
Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
Time frame: Week 12
A total of 554 potential participants were screened and 356 were excluded. Of the 198 participants randomized to study treatment, 147 (74.2%) completed the study.
| Milestone | Arm 1- Placebo | Arm 2- 25 μg MM120 | Arm 3- 50 μg MM120 | Arm 4- 100 μg MM120 | Arm 5- 200 μg MM120 |
|---|---|---|---|---|---|
| Started | 39 | 39 | 40 | 40 | 40 |
| Completed | 26 | 29 | 29 | 33 | 30 |
| Not completed | 13 | 10 | 11 | 7 | 10 |
To investigate the dose-response relationship for different doses of MM120 versus placebo in change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score at Week 4. The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety: Anxious mood, Tension, Fears, Insomnia, Intellectual, Depressed mood, Somatic (muscular), Somatic (sensory), Cardiovascular symptoms, Respiratory symptoms, Gastrointestinal symptoms, Genitourinary symptoms, Autonomic symptoms, and Behavior at interview (general). The central rater assessed the extent to which the subject displayed each given criterion and gave a rating on a scale of 0-4, where 4 represents the most severe symptoms. Minimum score = 0, maximum score = 56. Scores are summed and the greater the total score, the more severe illness.
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Mean Change from Baseline to Week 4 in HAM-A total score Model Averaging Method | -14.23 (-17.83 to -10.63) | -15.35 (-17.62 to -13.09) | -16.05 (-19.40 to -12.71) | -19.22 (-21.73 to -16.70) | -20.09 (-22.87 to -17.31) |
| Mean Difference in HAM-A total score from Placebo | 0.0 (0.0 to 0.0) | -1.24 (-6.01 to 3.53) | -1.82 (-7.65 to 4.00) | -5.02 (-9.60 to -0.44) | -5.95 (-9.84 to -2.06) |
To investigate the dose-response relationship for different doses of MM120 versus placebo in change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score at Week 8. The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety: Anxious mood, Tension, Fears, Insomnia, Intellectual, Depressed mood, Somatic (muscular), Somatic (sensory), Cardiovascular symptoms, Respiratory symptoms, Gastrointestinal symptoms, Genitourinary symptoms, Autonomic symptoms, and Behavior at interview (general). The central rater assessed the extent to which the subject displayed each given criterion and gave a rating on a scale of 0-4, where 4 represents the most severe symptoms. Minimum score = 0, maximum score = 56. Scores are summed and the greater the total score, the more severe illness.
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Mean change from Baseline to Week 8 HAM-A total score from Model Averaging Method | -15.51 (-17.79 to -13.23) | -16.24 (-18.12 to -14.36) | -16.90 (-18.70 to -15.09) | -18.39 (-20.17 to -16.61) | -20.94 (-23.92 to -17.95) |
| Mean difference from Placebo at Week 8 | 0.0 (0 to 0) | -0.76 (-1.72 to 0.20) | -1.44 (-3.08 to 0.20) | -2.92 (-5.37 to -0.46) | -5.43 (-9.46 to -1.39) |
To determine the change from Baseline of 4 doses of MM120 (25, 50, 100 or 200 μg free base equivalent) compared to Placebo as measured by the change in HAM-A Total Score from Baseline to Week 4 Hamilton Anxiety Rating Scale (HAM-A) consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety: Anxious mood, Tension, Fears, Insomnia, Intellectual, Depressed mood, Somatic (muscular), Somatic (sensory), Cardiovascular symptoms, Respiratory symptoms, Gastrointestinal symptoms, Genitourinary symptoms, Autonomic symptoms, and Behavior at interview (general). The central rater assessed the extent to which the subject displayed each given criterion and gave a rating on a scale of 0-4, where 4 represents the most severe symptoms. Minimum score = 0, maximum score = 56. Scores are summed and the greater the total score, the more severe illness. Data shown are change in HAM-A Total Score from Baseline to Week 4
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change From Baseline in HAM-A Total Score | -13.6 ± 9.79 | -17.2 ± 10.53 | -14.8 ± 9.96 | -20.9 ± 9.72 | -19.7 ± 9.48 |
To determine the change from Baseline in HAM-A total scores of 4 doses of MM120 (25, 50, 100 or 200 μg free base equivalent) compared with placebo from Baseline to Week 8. Hamilton Anxiety Rating Scale (HAM-A) consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety: Anxious mood, Tension, Fears, Insomnia, Intellectual, Depressed mood, Somatic (muscular), Somatic (sensory), Cardiovascular symptoms, Respiratory symptoms, Gastrointestinal symptoms, Genitourinary symptoms, Autonomic symptoms, and Behavior at interview (general). The central rater assessed the extent to which the subject displayed each given criterion and gave a rating on a scale of 0-4, where 4 represents the most severe symptoms. Minimum score = 0, maximum score = 56. Scores are summed and the greater the total score, the more severe illness. Data shown are change in HAM-A Total Score from Baseline to Week 8
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change From Baseline in HAM-A Total Scores | -15.4 ± 9.72 | -18.6 ± 10.91 | -14.5 ± 10.15 | -19.4 ± 10.28 | -21.1 ± 10.37 |
To determine the change from Baseline in HAM-A total scores of 4 doses of MM120 (25, 50, 100 or 200 μg free base equivalent) compared with placebo from Baseline to End of Study (Week 12). Hamilton Anxiety Rating Scale (HAM-A) consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety: Anxious mood, Tension, Fears, Insomnia, Intellectual, Depressed mood, Somatic (muscular), Somatic (sensory), Cardiovascular symptoms, Respiratory symptoms, Gastrointestinal symptoms, Genitourinary symptoms, Autonomic symptoms, and Behavior at interview (general). The central rater assessed the extent to which the subject displayed each given criterion and gave a rating on a scale of 0-4, where 4 represents the most severe symptoms. Minimum score = 0, maximum score = 56. Scores are summed and the greater the total score, the more severe illness. Data shown are change in HAM-A Total Score from Baseline to end of study (12 weeks)
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change From Baseline in HAM-A Total Scores | -14.3 ± 11.95 | -18.7 ± 10.85 | -17.3 ± 10.71 | -21.1 ± 10.35 | -22.0 ± 11.85 |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in depressive symptoms as measured by the MADRS. The Montgomery-Åsberg Depression Rating Scale (MADRS) - used to assess depression severity and to detect changes due to treatment. Questionnaire included 10 clinician-completed items. Each of 10 questions scored with a range of 0-6 points. An item score of 0 indicated item not present or normal, while an item score of 6 indicated severe or continuous presence of the symptoms. The total possible score was 60, and higher scores represented a more severe condition. A decrease in score by ≥ 50% indicated a response to treatment, and an actual score of ≤ 10 indicated a remission of symptoms.
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores | -11.0 ± 11.62 | -12.3 ± 10.45 | -11.1 ± 10.59 | -17.6 ± 11.21 | -17.4 ± 10.66 |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in depressive symptoms measured via the MADRS. The Montgomery-Åsberg Depression Rating Scale (MADRS) - used to assess depression severity and to detect changes due to treatment. Questionnaire included 10 clinician-completed items. Each of 10 questions scored with a range of 0-6 points. An item score of 0 indicated item not present or normal, while an item score of 6 indicated severe or continuous presence of the symptoms. The total possible score was 60, and higher scores represented a more severe condition. A decrease in score by ≥ 50% indicated a response to treatment, and an actual score of ≤ 10 indicated a remission of symptoms.
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores | -11.0 ± 11.59 | -12.7 ± 12.36 | -12.2 ± 10.50 | -17.3 ± 11.0 | -18.8 ± 10.33 |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in depressive symptoms measured via the MADRS. The Montgomery-Åsberg Depression Rating Scale (MADRS) - used to assess depression severity and to detect changes due to treatment. Questionnaire included 10 clinician-completed items. Each of 10 questions scored with a range of 0-6 points. An item score of 0 indicated item not present or normal, while an item score of 6 indicated severe or continuous presence of the symptoms. The total possible score was 60, and higher scores represented a more severe condition. A decrease in score by ≥ 50% indicated a response to treatment, and an actual score of ≤ 10 indicated a remission of symptoms.
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores | -12.4 ± 9.96 | -11.4 ± 11.63 | -12.3 ± 10.99 | -18.1 ± 11.97 | -18.3 ± 11.69 |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in depressive symptoms measured via the MADRS. The Montgomery-Åsberg Depression Rating Scale (MADRS) - used to assess depression severity and to detect changes due to treatment. Questionnaire included 10 clinician-completed items. Each of 10 questions scored with a range of 0-6 points. An item score of 0 indicated item not present or normal, while an item score of 6 indicated severe or continuous presence of the symptoms. The total possible score was 60, and higher scores represented a more severe condition. A decrease in score by ≥ 50% indicated a response to treatment, and an actual score of ≤ 10 indicated a remission of symptoms.
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores | -12.2 ± 9.63 | -12.5 ± 11.88 | -11.1 ± 11.59 | -17.2 ± 12.66 | -18.6 ± 10.84 |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in depressive symptoms measured via the MADRS. The Montgomery-Åsberg Depression Rating Scale (MADRS) - used to assess depression severity and to detect changes due to treatment. Questionnaire included 10 clinician-completed items. Each of 10 questions scored with a range of 0-6 points. An item score of 0 indicated item not present or normal, while an item score of 6 indicated severe or continuous presence of the symptoms. The total possible score was 60, and higher scores represented a more severe condition. A decrease in score by ≥ 50% indicated a response to treatment, and an actual score of ≤ 10 indicated a remission of symptoms.
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores | -12.3 ± 9.53 | -13.9 ± 11.29 | -14.6 ± 8.57 | -18.7 ± 11.47 | -19.9 ± 11.15 |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-S. The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. (minimum score 1, maximum score 7)
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| change from Baseline | -1.0 (-1.46 to -0.54) | -1.8 (-2.18 to -1.34) | -1.7 (-2.20 to -1.19) | -2.3 (-2.67 to -1.85) | -2.4 (-2.80 to -1.97) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -0.76 (-1.38 to -0.15) | -0.69 (-1.37 to -0.02) | -1.26 (-1.87 to -0.66) | -1.39 (-2.00 to -0.78) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-S. The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. (minimum score 1, maximum score 7)
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| change from baseline | -1.1 (-1.61 to -0.67) | -1.7 (-2.16 to -1.26) | -1.8 (-2.35 to -1.30) | -2.4 (-2.81 to -1.98) | -2.5 (-2.89 to -2.14) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -0.57 (-1.21 to 0.07) | -0.68 (-1.38 to 0.01) | -1.26 (-1.87 to -0.64) | -1.37 (-1.97 to -0.78) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-S. The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. (minimum score 1, maximum score 7)
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | -1.3 (-1.85 to -0.79) | -1.8 (-2.25 to -1.28) | -1.7 (-2.12 to -1.19) | -2.5 (-2.93 to -2.05) | -2.3 (-2.74 to -1.88) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -0.44 (-1.15 to 0.26) | -0.33 (-1.03 to 0.36) | -1.16 (-1.84 to -0.49) | -0.99 (-1.65 to -0.32) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-S. The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. (minimum score 1, maximum score 7)
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | -1.5 (-2.15 to -0.88) | -1.8 (-2.28 to -1.34) | -1.7 (-2.18 to -1.13) | -2.3 (-2.74 to -1.83) | -2.5 (-2.99 to -2.04) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -0.29 (-1.07 to 0.48) | -0.14 (-0.94 to 0.67) | -0.77 (-1.53 to 0.00) | -1.00 (-1.77 to -0.22) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-S. The Clinical Global Impression - Severity (CGI-S) was used to assess the subject's current severity of illness at the time of the assessment relative to the clinician's past experience with patients who have the same diagnosis. The CGI-S comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. (minimum score 1, maximum score 7)
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | -1.4 (-2.08 to -0.77) | -1.8 (-2.37 to -1.29) | -2.1 (-2.59 to -1.55) | -2.6 (-3.02 to -2.19) | -2.5 (-3.08 to -1.95) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -0.40 (-1.24 to 0.43) | -0.65 (-1.46 to 0.17) | -1.18 (-1.95 to -0.42) | -1.09 (-1.94 to -0.24) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-I. The Clinical Global Impression - Improvement (CGI-I) was used to measure the clinician's assessment of how much the subject's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening. (minimum score 1, maximum score 7)
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Actual Values CGI-I | 3.1 (2.69 to 3.49) | 2.4 (2.07 to 2.67) | 2.3 (1.98 to 2.69) | 1.8 (1.55 to 2.03) | 1.9 (1.61 to 2.16) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -0.72 (-1.21 to -0.23) | -0.75 (-1.28 to -0.23) | -1.30 (-1.76 to -0.84) | -1.20 (-1.68 to -0.73) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-I. The Clinical Global Impression - Improvement (CGI-I) was used to measure the clinician's assessment of how much the subject's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening. (minimum score 1, maximum score 7)
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Actual values (CGI-I scores) | 3.0 (2.62 to 3.44) | 2.5 (2.13 to 2.87) | 2.4 (1.92 to 2.78) | 1.7 (1.43 to 1.94) | 1.9 (1.67 to 2.17) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -0.53 (-1.07 to 0.02) | -0.67 (-1.26 to -0.09) | -1.34 (-1.82 to -0.87) | -1.11 (-1.58 to -0.64) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-I. The Clinical Global Impression - Improvement (CGI-I) was used to measure the clinician's assessment of how much the subject's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening. (minimum score 1, maximum score 7)
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Actual value (CGI-I score) | 2.8 (2.27 to 3.28) | 2.4 (2.00 to 2.82) | 2.4 (1.99 to 2.86) | 1.8 (1.51 to 2.08) | 2.2 (1.76 to 2.55) |
| Difference in Means (MM120-placebo) | 0 (0 to 0) | -.036 (-1.00 to 0.28) | -0.35 (-1.00 to 0.31) | -0.98 (-1.56 to -0.40) | -0.62 (-1.25 to 0.01) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-I. The Clinical Global Impression - Improvement (CGI-I) was used to measure the clinician's assessment of how much the subject's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening. (minimum score 1, maximum score 7).
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Actual vaues (CGI-I scores) | 2.7 (2.23 to 3.25) | 2.2 (1.86 to 2.58) | 2.7 (2.08 to 3.23) | 1.8 (1.51 to 2.15) | 2.0 (1.63 to 2.31) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -0.52 (-1.14 to 0.09) | -0.08 (-0.84 to 0.67) | -0.91 (-1.50 to -0.32) | -0.77 (-1.37 to -0.17) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the CGI-I. The Clinical Global Impression - Improvement (CGI-I) was used to measure the clinician's assessment of how much the subject's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises 1 Investigator-completed (or trained rater-completed) item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening. (minimum score 1, maximum score 7)
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Actual values (CGI-I scores) | 2.7 (2.19 to 3.27) | 2.3 (1.96 to 2.66) | 2.2 (1.68 to 2.73) | 1.6 (1.34 to 1.93) | 1.9 (1.46 to 2.35) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -0.42 (-1.06 to 0.21) | -0.52 (-1.26 to 0.21) | -1.09 (-1.70 to -0.49) | -0.83 (-1.52 to -0.14) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-S. The Patient Global Impression - Severity (PGI-S) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure disease severity (PGI-S). The PGI-S comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates more severe illness. (minimum score 1, maximum score 5)
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | -0.7 (-0.98 to -0.43) | -1.3 (-1.55 to -0.98) | -1.2 (-1.55 to -0.90) | -1.6 (-1.84 to -1.27) | -1.6 (-1.91 to -1.32) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -0.56 (-0.95 to -0.17) | -0.52 (-0.94 to -0.10) | -0.85 (-1.24 to -0.46) | -0.91 (-1.30 to -0.51) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-S. The Patient Global Impression - Severity (PGI-S) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure disease severity (PGI-S). The PGI-S comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates more severe illness. (minimum score 1, maximum score 5)
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | -0.8 (-1.10 to -0.45) | -1.2 (-1.49 to -0.83) | -1.3 (-1.65 to -0.88) | -1.5 (-1.80 to -1.15) | -1.6 (-1.88 to -1.26) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -0.38 (-0.84 to 0.07) | -0.49 (-0.98 to 0.01) | -0.70 (-1.15 to -0.25) | -0.79 (-1.23 to -0.35) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-S. The Patient Global Impression - Severity (PGI-S) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure disease severity (PGI-S). The PGI-S comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates more severe illness. (minimum score 1, maximum score 5)
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | -1.0 (-1.35 to -0.65) | -1.3 (-1.70 to -0.95) | -1.3 (-1.66 to -0.97) | -1.5 (-1.78 to -1.19) | -1.6 (-1.94 to -1.19) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -0.32 (-0.83 to 0.18) | -0.31 (-0.80 to 0.17) | -0.49 (-0.94 to -0.03) | -0.56 (-1.07 to -0.06) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-S. The Patient Global Impression - Severity (PGI-S) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure disease severity (PGI-S). The PGI-S comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates more severe illness. (minimum score 1, maximum score 5)
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | -1.0 (-1.41 to -0.52) | -1.3 (-1.67 to -0.95) | -1.1 (-1.58 to -0.61) | -1.4 (-1.70 to -1.05) | -1.6 (-2.05 to -1.22) |
| difference in means (MM120-placebo) | 0 (0 to 0) | -0.35 (-0.91 to 0.21) | -0.13 (-0.78 to 0.52) | -0.41 (-0.95 to 0.13) | -0.67 (-1.27 to -0.08) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-S. The Patient Global Impression - Severity (PGI-S) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure disease severity (PGI-S). The PGI-S comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates more severe illness. (minimum score 1, maximum score 5)
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | -1.1 (-1.57 to -0.58) | -1.4 (-1.73 to -1.10) | -1.4 (-1.80 to -0.96) | -1.5 (-1.87 to -1.22) | -1.5 (-1.86 to -1.04) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -0.34 (-0.91 to 0.24) | -0.30 (-0.94 to 0.34) | -0.47 (-1.05 to 0.11) | -0.37 (-1.01 to 0.26) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-C. The Patient Global Impression - Change (PGI-C) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure changes in disease severity (PGI-C). The PGI-C comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates change for the worse (worsening symptoms). (minimum score 1, maximum score 5)
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Actual Values PGI-C | 2.3 (1.96 to 2.69) | 2.0 (1.74 to 2.26) | 1.8 (1.49 to 2.12) | 1.3 (1.14 to 1.55) | 1.5 (1.29 to 1.76) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -0.32 (-0.76 to 0.12) | -0.52 (-0.99 to -0.05) | -0.98 (-1.39 to -0.57) | -0.80 (-1.22 to -0.37) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-C. The Patient Global Impression - Change (PGI-C) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure changes in disease severity (PGI-C). The PGI-C comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates change for the worse (worsening symptoms). (minimum score 1, maximum score 5)
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Actual values PGI-C | 2.4 (2.01 to 2.72) | 1.9 (1.61 to 2.28) | 2.0 (1.61 to 2.39) | 1.6 (1.31 to 1.85) | 1.5 (1.20 to 1.72) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -0.42 (-0.89 to 0.06) | -0.36 (-0.88 to 0.16) | -0.78 (-1.22 to -0.34) | -0.90 (-1.33 to -0.47) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-C. The Patient Global Impression - Change (PGI-C) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure changes in disease severity (PGI-C). The PGI-C comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates change for the worse (worsening symptoms). (minimum score 1, maximum score 5)
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Actual values PGI-C | 2.3 (1.85 to 2.67) | 2.0 (1.63 to 2.43) | 1.9 (1.53 to 2.24) | 1.4 (1.17 to 1.55) | 1.7 (1.38 to 2.01) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -0.23 (-0.79 to 0.33) | -0.37 (-0.90 to 0.16) | -0.90 (-1.35 to -0.45) | -0.57 (-1.08 to -0.05) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-C. The Patient Global Impression - Change (PGI-C) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure changes in disease severity (PGI-C). The PGI-C comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates change for the worse (worsening symptoms). (minimum score 1, maximum score 5)
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Actual values PGI-C | 2.1 (1.79 to 2.51) | 1.7 (1.46 to 1.98) | 2.0 (1.64 to 2.42) | 1.5 (1.27 to 1.81) | 1.8 (1.41 to 2.10) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -0.43 (-0.87 to 0.01) | -0.12 (-0.64 to 0.40) | -0.61 (-1.04 to -0.17) | -0.39 (-0.88 to 0.10) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in anxiety symptoms measured via the PGI-C. The Patient Global Impression - Change (PGI-C) is the patient-reported outcome counterpart to the CGI scale. The PGI is adapted to the patient population and can be used to measure changes in disease severity (PGI-C). The PGI-C comprises 1 subject-completed item with 5 possible ratings (1-5). A higher score indicates change for the worse (worsening symptoms). (minimum score 1, maximum score 5)
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Actual values PGI-C | 2.2 (1.80 to 2.59) | 1.8 (1.56 to 2.10) | 1.8 (1.45 to 2.21) | 1.5 (1.25 to 1.72) | 1.7 (1.32 to 2.04) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -0.36 (-0.83 to 0.10) | -0.36 (-0.90 to 0.17) | -0.71 (-1.16 to -0.25) | -0.51 (-1.04 to 0.01) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in functional disability symptoms measured via the SDS. The Sheehan Disability Scale (SDS) is a composite of 3 self-rated items designed to measure the extent to which 3 major domains in the patient's life (work, social life/leisure activities and family life/home responsibilities) are functionally impaired by psychiatric or medical symptoms. Total score 0-30 (0 unimpaired, 30 highly impaired). Work/school (0-10); Social life (0-10); Family life/home responsibilities (0-10).
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | -7.4 (-10.00 to -4.83) | -8.8 (-10.91 to -6.67) | -8.0 (-10.73 to -5.33) | -14.6 (-16.67 to -12.49) | -13.6 (-15.61 to -11.59) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -1.38 (-4.66 to 1.91) | -0.62 (-4.29 to 3.05) | -7.17 (-10.44 to -3.90) | -6.19 (-9.40 to -2.97) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in functional disability symptoms measured via the SDS. The Sheehan Disability Scale (SDS) is a composite of 3 self-rated items designed to measure the extent to which 3 major domains in the patient's life (work, social life/leisure activities and family life/home responsibilities) are functionally impaired by psychiatric or medical symptoms. Total score 0-30 (0 unimpaired, 30 highly impaired). Work/school (0-10); Social life (0-10); Family life/home responsibilities (0-10).
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from Baseline | -7.8 (-10.49 to -5.18) | -9.8 (-12.32 to -7.30) | -8.2 (-11.04 to -5.43) | -14.0 (-16.23 to -11.71) | -14.2 (-16.42 to -11.97) |
| Difference in means (MM120-placeb) | 0 (0 to 0) | -1.98 (-5.57 to 1.61) | -0.40 (-4.20 to 3.39) | -6.14 (-9.57 to -2.71) | -6.36 (-9.77 to -2.95) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in functional disability symptoms measured via the SDS. The Sheehan Disability Scale (SDS) is a composite of 3 self-rated items designed to measure the extent to which 3 major domains in the patient's life (work, social life/leisure activities and family life/home responsibilities) are functionally impaired by psychiatric or medical symptoms. Total score 0-30 (0 unimpaired, 30 highly impaired). Work/school (0-10); Social life (0-10); Family life/home responsibilities (0-10).
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | -9.0 (-12.03 to -5.90) | -9.5 (-12.24 to -6.67) | -8.7 (-11.41 to -5.94) | -14.9 (-17.18 to -12.66) | -13.5 (-15.88 to -11.04) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -0.49 (-4.55 to 3.58) | 0.29 (-3.74 to 4.32) | -5.96 (-9.70 to -2.21) | -4.49 (-8.33 to -0.66) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in functional disability symptoms measured via the SDS. The Sheehan Disability Scale (SDS) is a composite of 3 self-rated items designed to measure the extent to which 3 major domains in the patient's life (work, social life/leisure activities and family life/home responsibilities) are functionally impaired by psychiatric or medical symptoms. Total score 0-30 (0 unimpaired, 30 highly impaired). Work/school (0-10); Social life (0-10); Family life/home responsibilities (0-10).
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | -9.1 (-12.62 to -5.68) | -10.5 (-13.21 to -7.73) | -7.5 (-10.77 to -4.17) | -13.8 (-16.48 to -11.18) | -13.6 (-16.39 to -10.76) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -1.32 (-5.65 to 3.01) | 1.68 (-3.01 to 6.37) | -4.68 (-8.96 to -0.40) | -4.43 (-8.81 to -0.05) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in functional disability symptoms measured via the SDS. The Sheehan Disability Scale (SDS) is a composite of 3 self-rated items designed to measure the extent to which 3 major domains in the patient's life (work, social life/leisure activities and family life/home responsibilities) are functionally impaired by psychiatric or medical symptoms. Total score 0-30 (0 unimpaired, 30 highly impaired). Work/school (0-10); Social life (0-10); Family life/home responsibilities (0-10).
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | -8.2 (-11.75 to -4.65) | -10.8 (-13.73 to -7.85) | -9.0 (-12.52 to -5.54) | -15.1 (-17.11 to -13.01) | -13.1 (-15.88 to -10.37) |
| Difference in means (MM120-plcebo) | 0 (0 to 0) | -2.59 (-7.10 to 1.91) | -0.83 (-5.70 to 4.03) | -6.86 (-10.89 to -2.83) | -4.93 (-9.33 to -0.53) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in quality of life. The EuroQol 5 Dimension 5 Level (EQ-5D-5L) was used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The VAS for the subject's health status scored as ranging from 0 = worst health you can imagine, to 100 = best health you can imagine.
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | 6.9 (1.08 to 12.69) | 11.2 (4.57 to 17.85) | 12.3 (7.15 to 17.46) | 15.7 (10.20 to 21.12) | 14.9 (9.79 to 19.93) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | 4.33 (-4.34 to 13.00) | 5.43 (-2.20 to 13.05) | 8.78 (0.95 to 16.60) | 7.98 (0.41 to 15.55) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in quality of life. The EuroQol 5 Dimension 5 Level (EQ-5D-5L) was used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The VAS for the subject's health status scored as ranging from 0 = worst health you can imagine, to 100 = best health you can imagine.
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | 10.3 (5.49 to 15.12) | 11.8 (4.66 to 18.85) | 10.6 (5.51 to 15.61) | 14.7 (9.72 to 19.64) | 15.9 (10.46 to 21.27) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | 1.45 (-6.99 to 9.89) | 0.25 (-6.60 to 7.10) | 4.38 (-2.41 to 11.17) | 5.56 (-1.55 to 12.67) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in quality of life. The EuroQol 5 Dimension 5 Level (EQ-5D-5L) was used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The VAS for the subject's health status scored as ranging from 0 = worst health you can imagine, to 100 = best health you can imagine.
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | 11.5 (5.79 to 17.17) | 13.5 (5.76 to 21.33) | 10.5 (4.76 to 16.33) | 15.5 (10.27 to 20.73) | 15.7 (9.02 to 22.32) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | 2.03 (-7.41 to 11.53) | -0.94 (-8.90 to 7.02) | 4.02 (-3.57 to 11.60) | 4.18 (-4.41 to 12.78) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in quality of life. The EuroQol 5 Dimension 5 Level (EQ-5D-5L) was used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The VAS for the subject's health status scored as ranging from 0 = worst health you can imagine, to 100 = best health you can imagine.
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | 10.8 (3.97 to 17.66) | 16.2 (10.20 to 22.18) | 9.7 (3.37 to 16.07) | 16.2 (9.94 to 22.52) | 17.0 (10.07 to 23.93) |
| Diference in means (MM120-placebo) | 0 (0 to 0) | 5.37 (-3.53 to 14.28) | -1.10 (-10.23 to 8.04) | 5.41 (-3.69 to 14.52) | 6.19 (-3.35 to 15.72) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in quality of life. The EuroQol 5 Dimension 5 Level (EQ-5D-5L) was used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The VAS for the subject's health status scored as ranging from 0 = worst health you can imagine, to 100 = best health you can imagine.
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | 11.7 (4.28 to 19.02) | 17.0 (9.92 to 24.01) | 13.2 (7.89 to 18.52) | 17.7 (12.85 to 22.55) | 17.3 (10.18 to 24.40) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | 5.31 (-4.65 to 15.27) | 1.55 (-7.34 to 10.45) | 6.04 (-2.61 to 14.70) | 5.64 (-4.37 to 15.65) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in sleep measured via the PSQI. The Pittsburgh Sleep Quality Index (PSQI) was used to assess sleep quality and disturbances over the preceding month. The questionnaire had a Component Score for each of these with a range of 0-3 points: Subjective sleep quality, Sleep latency, Sleep duration, Habitual sleep efficiency, Sleep disturbance, Use of sleeping medication, and Daytime dysfunction. The sum of the Component Scores = a Global Score. Global Score of 0 indicated no difficulty and a Global Score of 21 indicated severe difficulty in all areas.
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | -3.7 (-5.10 to -2.21) | -3.8 (-5.20 to -2.37) | -2.7 (-4.32 to -1.14) | -5.3 (-6.57 to -4.01) | -3.9 (-5.04 to -2.75) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -0.13 (-2.11 to 1.86) | 0.93 (-1.18 to 3.04) | -1.63 (-3.53 to 0.26) | -0.24 (-2.05 to 1.57) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in sleep measured via the PSQI. The Pittsburgh Sleep Quality Index (PSQI) was used to assess sleep quality and disturbances over the preceding month. The questionnaire had a Component Score for each of these with a range of 0-3 points: Subjective sleep quality, Sleep latency, Sleep duration, Habitual sleep efficiency, Sleep disturbance, Use of sleeping medication, and Daytime dysfunction. The sum of the Component Scores = a Global Score. Global Score of 0 indicated no difficulty and a Global Score of 21 indicated severe difficulty in all areas.
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | -4.1 (-5.70 to -2.60) | -5.4 (-6.97 to -3.80) | -3.6 (-5.21 to -1.98) | -5.1 (-6.61 to -3.67) | -4.4 (-5.94 to -2.88) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -1.24 (-3.41 to 0.93) | 0.55 (-1.63 to 2.74) | -0.99 (-3.09 to 1.10) | -0.26 (-2.39 to 1.87) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in subjects with anxiety symptoms, including improvements in sleep measured via the PSQI. The Pittsburgh Sleep Quality Index (PSQI) was used to assess sleep quality and disturbances over the preceding month. The questionnaire had a Component Score for each of these with a range of 0-3 points: Subjective sleep quality, Sleep latency, Sleep duration, Habitual sleep efficiency, Sleep disturbance, Use of sleeping medication, and Daytime dysfunction. The sum of the Component Scores = a Global Score. Global Score of 0 indicated no difficulty and a Global Score of 21 indicated severe difficulty in all areas.
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | -4.3 (-5.97 to -2.56) | -5.5 (-7.04 to -3.99) | -4.8 (-6.33 to -3.32) | -5.9 (-7.37 to -4.45) | -4.9 (-6.38 to -3.36) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -1.25 (-3.48 to 0.99) | -0.55 (-2.77 to 1.67) | -1.64 (-3.84 to 0.56) | -0.60 (-2.83 to 1.62) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in female subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | -2.1 (-4.46 to 0.20) | -1.4 (-3.70 to 0.90) | -1.9 (-3.54 to -0.16) | -3.1 (-5.56 to -0.58) | -2.5 (-4.35 to -0.73) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | 0.73 (-2.44 to 3.90) | 0.28 (-2.52 to 3.08) | -0.94 (-4.22 to 2.35) | -0.41 (-3.29 to 2.46) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in female subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | -1.0 (-2.83 to 0.83) | -2.2 (-4.07 to -0.33) | 0.4 (-1.33 to 2.18) | -2.4 (-4.70 to -0.02) | -2.2 (-4.10 to -0.34) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -1.20 (-3.74 to 1.34) | 1.42 (-1.04 to 3.88) | -1.36 (-4.22 to 1.50) | -1.22 (-3.78 to 1.34) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in female subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from Baseline | -3.6 (-6.07 to -1.17) | -2.5 (-3.99 to -1.01) | -1.1 (-2.72 to 0.51) | -3.3 (-5.76 to -0.77) | -1.2 (-3.17 to 0.81) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | 1.12 (-1.67 to 3.91) | 2.51 (-0.34 to 5.37) | 0.35 (-3.01 to 3.72) | 2.44 (-0.63 to 5.51) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in female subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | -4.4 (-7.33 to -1.51) | -2.0 (-3.74 to -0.26) | -0.7 (-2.29 to 0.88) | -1.8 (-4.19 to 0.65) | -2.8 (-4.38 to -1.20) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | 2.42 (-0.87 to 5.71) | 3.72 (0.49 to 6.94) | 2.65 (-0.97 to 6.27) | 1.63 (-1.61 to 4.87) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in female subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | -3.9 (-6.77 to -1.12) | -2.7 (-4.83 to -0.55) | -1.3 (-3.56 to 0.90) | -2.8 (-5.45 to -0.09) | -2.7 (-4.38 to -1.05) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | 1.26 (-2.15 to 4.67) | 2.61 (-0.85 to 6.07) | 1.18 (-2.54 to 4.89) | 1.23 (-1.96 to 4.42) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in male subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | 0.1 (-1.88 to 2.08) | -1.4 (-2.57 to -0.21) | -0.6 (-2.88 to 1.63) | -1.1 (-2.90 to 0.63) | -1.1 (-3.41 to 1.24) |
| Difference in mean (MM120-placebo) | 0 (0 to 0) | -1.49 (-3.69 to 0.71) | -0.73 (-3.56 to 2.11) | -1.24 (-3.75 to 1.28) | -1.18 (-4.04 to 1.68) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in male subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | 0.0 (-2.23 to 2.23) | -1.1 (-2.51 to 0.28) | -0.5 (-3.06 to 2.13) | -1.3 (-2.71 to 0.21) | -0.6 (-2.39 to 1.19) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -1.12 (-3.63 to 1.39) | -0.47 (-3.71 to 2.77) | -1.25 (-3.80 to 1.30) | -0.60 (-3.28 to 2.08) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in male subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | -0.2 (-2.53 to 2.13) | -1.3 (-3.17 to 0.50) | -0.9 (-3.02 to 1.27) | -2.1 (-3.97 to -0.29) | -1.6 (-5.33 to 2.06) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -1.13 (-3.93 to 1.66) | -0.68 (-3.66 to 2.31) | -1.93 (-4.75 to 0.89) | -1.44 (-5.57 to 2.69) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in male subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | -1.1 (-6.05 to 3.80) | -1.3 (-3.46 to 0.89) | -1.4 (-3.07 to 0.27) | -2.0 (-3.47 to -0.43) | -3.2 (-8.19 to 1.74) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -0.16 (-5.29 to 4.97) | -0.28 (-5.30 to 4.75) | -0.83 (-5.84 to 4.18) | -2.10 (-8.48 to 4.29) |
To determine whether MM120 (25, 50, 100, or 200 µg freebase-equivalent) improves functionality and quality of life measures in male subjects with anxiety symptoms, including improvements in sexual function measured via the ASEX. The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
| units on a scale | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Change from baseline | -0.3 (-2.73 to 2.23) | -1.3 (-2.93 to 0.32) | -2.4 (-3.86 to -1.00) | -1.9 (-3.21 to -0.59) | -2.5 (-6.35 to 1.35) |
| Difference in means (MM120-placebo) | 0 (0 to 0) | -1.06 (-3.82 to 1.70) | -2.18 (-4.86 to 0.51) | -1.65 (-4.30 to 1.00) | -2.25 (-6.52 to 2.02) |
Number of Participants with sexual dysfunction n (%) vs Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
| Participants | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Number of Participants with sexual dysfunction | 12 | 10 | 9 | 6 | 8 |
| Number of Participants without sexual dysfunction | 11 | 10 | 11 | 10 | 16 |
Number of Participants with sexual dysfunction n (%) vs Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
| Participants | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Number of Participants with sexual dysfunction | 14 | 7 | 14 | 5 | 10 |
| Number of Participants without sexual dysfunction | 11 | 13 | 5 | 9 | 17 |
Number of Participants with sexual dysfunction n (%) vs Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
| Participants | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Number of Participants with sexual dysfunction | 8 | 6 | 11 | 6 | 10 |
| Number of Participants without sexual dysfunction | 13 | 13 | 8 | 10 | 18 |
Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
| Participants | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Number of Participants with sexual dysfunction | 5 | 6 | 11 | 6 | 8 |
| Number of Participants without sexual dysfunction | 14 | 11 | 6 | 8 | 16 |
Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
| Participants | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Number of Participants with sexual dysfunction | 6 | 4 | 10 | 6 | 7 |
| Number of Participants without sexual dysfunction | 12 | 12 | 5 | 7 | 14 |
Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
| Participants | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Number of Participants with sexual dysfunction | 1 | 4 | 3 | 2 | 3 |
| Number of Participants without sexual dysfunction | 9 | 14 | 13 | 20 | 9 |
Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
| Participants | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Number of Participants with sexual dysfunction | 0 | 3 | 3 | 2 | 1 |
| Number of Participants without sexual dysfunction | 11 | 14 | 12 | 22 | 9 |
Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
| Participants | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Number of Participants with sexual dysfunction | 0 | 3 | 4 | 1 | 0 |
| Number of Participants without sexual dysfunction | 10 | 12 | 12 | 22 | 11 |
Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
| Participants | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Number of Participants with sexual dysfunction | 1 | 3 | 4 | 1 | 1 |
| Number of Participants without sexual dysfunction | 7 | 12 | 11 | 20 | 8 |
Number of Participants with sexual dysfunction n (%) vs. Number of Participants without sexual dysfunction n (%). The Arizona Sexual Experiences Questionnaire (ASEX) is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm over the past week. Possible total scores on the ASEX range of 5-30, with a higher score indicating more sexual dysfunction.
| Participants | Arm 1- Placebo | Arm 2- 25 μg MM-120 (LSD D-Tartrate) | Arm 3- 50 μg MM-120 (LSD D-Tartrate) | Arm 4- 100 μg MM-120 (LSD D-Tartrate) | Arm 5- 200 μg MM-120 (LSD D-Tartrate) |
|---|---|---|---|---|---|
| Number of Participants with sexual dysfunction | 1 | 3 | 1 | 2 | 0 |
| Number of Participants without sexual dysfunction | 7 | 10 | 13 | 18 | 10 |
Collected over AE collection will occur from the time informed consent is given until Week 12 (or early discontinuation) and will be recorded at each visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1- Placebo | 0/39 (0%) | 0/39 (0%) | 22/39 (56.4%) |
| Arm 2- 25 μg MM120 | 0/39 (0%) | 0/39 (0%) | 30/39 (76.9%) |
| Arm 3- 50 μg MM120 | 0/40 (0%) | 1/40 (2.5%) | 36/40 (90%) |
| Arm 4- 100 μg MM120 | 0/40 (0%) | 0/40 (0%) | 39/40 (97.5%) |
| Arm 5- 200 μg MM120 | 0/40 (0%) | 0/40 (0%) | 40/40 (100%) |
| Event | Arm 1- Placebo | Arm 2- 25 μg MM120 | Arm 3- 50 μg MM120 | Arm 4- 100 μg MM120 | Arm 5- 200 μg MM120 |
|---|---|---|---|---|---|
| Panic AttackPsychiatric disorders | 0/39 | 0/39 | 1/40 | 0/40 | 0/40 |
| Event | Arm 1- Placebo | Arm 2- 25 μg MM120 | Arm 3- 50 μg MM120 | Arm 4- 100 μg MM120 | Arm 5- 200 μg MM120 |
|---|---|---|---|---|---|
| IllusionPsychiatric disorders | 3/39 | 12/39 | 18/40 | 25/40 | 30/40 |
| NauseaGastrointestinal disorders | 3/39 | 3/39 | 11/40 | 16/40 | 24/40 |
| HeadachesNervous system disorders | 9/39 | 5/39 | 9/40 | 14/40 | 11/40 |
| Euphoric moodPsychiatric disorders | 1/39 | 2/39 | 5/40 | 11/40 | 6/40 |
| Hallucination, visualPsychiatric disorders | 1/39 | 6/39 | 9/40 | 9/40 | 6/40 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/39 | 1/39 | 4/40 | 9/40 | 5/40 |
| MydriasisEye disorders | 1/39 | 1/39 | 7/40 | 8/40 | 4/40 |
| ParaesthesiaNervous system disorders | 3/39 | 2/39 | 2/40 | 2/40 | 8/40 |
| TremorNervous system disorders | 0/39 | 0/39 | 3/40 | 3/40 | 8/40 |
| AmxietyPsychiatric disorders | 2/39 | 4/39 | 5/40 | 4/40 | 6/40 |
There were 198 participants in the Randomized Set and 198 participants in the Safety Set. Of these, 194 (98.0%) of participants were included in the Full Analysis Set and 183 (92.4%) were included in the Per Protocol Set.
| Age, Continuous(years) | Arm 1- Placebo | Arm 2- 25 μg MM120 | Arm 3- 50 μg MM120 | Arm 4- 100 μg MM120 | Arm 5- 200 μg MM120 | Total |
|---|---|---|---|---|---|---|
| Mean | 38.7 ± 12.66 | 38.0 ± 12.08 | 45.3 ± 14.23 | 42.7 ± 14.79 | 42.1 ± 13.53 | 41.3 ± 13.61 |
| Sex: Female, Male(Participants) | Arm 1- Placebo | Arm 2- 25 μg MM120 | Arm 3- 50 μg MM120 | Arm 4- 100 μg MM120 | Arm 5- 200 μg MM120 | Total |
|---|---|---|---|---|---|---|
| Female | 26 | 20 | 20 | 16 | 28 | 110 |
| Male | 13 | 19 | 16 | 24 | 12 | 84 |
| Race (NIH/OMB)(Participants) | Arm 1- Placebo | Arm 2- 25 μg MM120 | Arm 3- 50 μg MM120 | Arm 4- 100 μg MM120 | Arm 5- 200 μg MM120 | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 1 | 3 | 0 | 1 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 3 | 2 | 1 | 3 | 15 |
| White | 30 | 33 | 29 | 36 | 33 | 161 |
| More than one race | 0 | 1 | 0 | 1 | 1 | 3 |
| Unknown or Not Reported | 1 | 1 | 2 | 2 | 2 | 8 |
| Region of Enrollment(participants) | Arm 1- Placebo | Arm 2- 25 μg MM120 | Arm 3- 50 μg MM120 | Arm 4- 100 μg MM120 | Arm 5- 200 μg MM120 | Total |
|---|---|---|---|---|---|---|
| United States | 39 | 39 | 36 | 40 | 40 | 194 |
| Baseline HAM-A Total Score(units on a scale) | Arm 1- Placebo | Arm 2- 25 μg MM120 | Arm 3- 50 μg MM120 | Arm 4- 100 μg MM120 | Arm 5- 200 μg MM120 | Total |
|---|---|---|---|---|---|---|
| Mean | 30.3 ± 6.56 | 30.2 ± 6.05 | 30.3 ± 5.71 | 29.3 ± 6.42 | 31.0 ± 6.98 | 30.1 ± 6.44 |
| Baseline MADRS Total Score(units on a scale) | Arm 1- Placebo | Arm 2- 25 μg MM120 | Arm 3- 50 μg MM120 | Arm 4- 100 μg MM120 | Arm 5- 200 μg MM120 | Total |
|---|---|---|---|---|---|---|
| Mean | 27.6 ± 9.69 | 25.4 ± 7.58 | 27.7 ± 8.30 | 26.5 ± 7.99 | 28.9 ± 8.31 | 27.2 ± 8.50 |
| Baseline PSQL Global Score(units on a scale) | Arm 1- Placebo | Arm 2- 25 μg MM120 | Arm 3- 50 μg MM120 | Arm 4- 100 μg MM120 | Arm 5- 200 μg MM120 | Total |
|---|---|---|---|---|---|---|
| Mean | 10.9 ± 4.15 | 10.7 ± 3.40 | 11.1 ± 3.43 | 11.0 ± 3.47 | 10.1 ± 3.33 | 10.8 ± 3.59 |
| Baseline CGI-S(units on a scale) | Arm 1- Placebo | Arm 2- 25 μg MM120 | Arm 3- 50 μg MM120 | Arm 4- 100 μg MM120 | Arm 5- 200 μg MM120 | Total |
|---|---|---|---|---|---|---|
| Mean | 4.9 ± 0.61 | 4.9 ± 0.75 | 4.9 ± 0.62 | 4.8 ± 0.75 | 5.1 ± 0.73 | 4.9 ± 0.70 |
6 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2022 to primary completion in Oct 2023, 13 months.
Results were first posted in Mar 2025, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lysergide D-tartrate
Generalized Anxiety Disorder →
Definium Therapeutics US, Inc.